Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2023-04-28 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物关于召开2022年度暨2023年第一季度业绩暨现金分红说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about an upcoming investor meeting to discuss the 2022 annual and 2023 first quarter performance and cash dividend. It provides details about the meeting time, location, participation method, and contact information. The document does not contain actual financial statements or detailed financial analysis but rather informs investors about the event where such information will be discussed. The document length is short (1549 characters) and it references the prior release of the 2022 annual report and 2023 first quarter report, indicating this is a notice about a presentation or meeting rather than the report itself. Therefore, it fits best as an Investor Presentation (IP) announcement or an AGM Information type. However, since it is specifically about an investor performance and dividend explanation meeting, it aligns most closely with Investor Presentation (IP).
2023-04-28 Chinese
安旭生物关于续聘2023年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of the audit firm 信永中和会计师事务所 for the 2023 fiscal year. It details the audit firm's background, personnel, independence, and the approval process including board and independent directors' opinions. It explicitly states that the reappointment is subject to approval at the 2022 annual shareholders meeting. The document does not contain any actual audit report, financial statements, or audit results, but rather is a formal announcement about the audit firm appointment process. The document length is 2887 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates to audit matters but is not a full annual report or audit report itself. However, since it is an announcement about the audit firm reappointment and not the audit report itself, it fits best under AR (Audit Report / Information) rather than 10-K or RPA. Confidence is high given the clear content and context. FY 2022
2023-04-28 Chinese
董事会审计委员会2022年度履职情况报告
Regulatory Filings
2023-04-28 Chinese
信永中和会计师事务所（特殊普通合伙）关于安旭生物2022年度内部控制审计报告
Regulatory Filings
2023-04-28 Chinese
安旭生物关于竞拍取得土地使用权的自愿性披露公告
Capital/Financing Update Classification · 95% confidence The document is a voluntary disclosure announcement by Hangzhou Anxu Biotech Co., Ltd. regarding the successful auction of land use rights. It details the transaction overview, land specifics, and the intended use of the land for company development. There is no financial report, earnings data, or regulatory certification. The document is an announcement about a capital asset acquisition, specifically land use rights, which relates to the company's capital structure and asset base. It is not a full financial report or audit, nor is it a voting result or management change. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on a significant capital asset acquisition by the company.
2023-04-11 Chinese
安旭生物关于公司全资二级子公司开立募集资金专用账户并签署募集资金专户存储四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the opening of a special account for raised funds by a wholly-owned subsidiary and the signing of a four-party supervision agreement related to the management and use of these funds. It references regulatory approvals, fund amounts, and agreements with banks and sponsors. The document is relatively short (2995 characters) and primarily provides details about the fund management arrangements rather than presenting financial statements or comprehensive financial data. It does not contain financial results, audit opinions, or detailed management analysis. Therefore, it is an announcement related to capital/financing activities, specifically about the management of raised funds and related agreements. This fits best under the category Capital/Financing Update (CAP).
2023-03-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.